

1 **Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-**  
2 **codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation**

3  
4 Nayan Lamba, M.D.<sup>1,2</sup>; Malia McAvoy, M.S.<sup>3,4</sup>; Vasileios K. Kavouridis, M.D., M.P.H.<sup>4,5</sup>; Timothy R.  
5 Smith, M.D., Ph.D., M.P.H.<sup>3,4</sup>; Mehdi Touat, M.D.<sup>6,7</sup>; David A. Reardon, M.D.<sup>3,8</sup>; J. Bryan Iorgulescu,  
6 M.D.<sup>3,4,9,10</sup>

7  
8 <sup>1</sup>Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA

9 <sup>2</sup>Department of Medicine, Cambridge Health Alliance, Cambridge, MA

10 <sup>3</sup>Harvard Medical School, Boston, MA

11 <sup>4</sup>Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's  
12 Hospital, Boston, MA

13 <sup>5</sup>Department of Surgery, St. Elizabeth's Medical Center, Brighton, MA

14 <sup>6</sup>Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA

15 <sup>7</sup>Sorbonne Université; Institut du Cerveau et de la Moelle épinière; Service de Neurologie, Hôpitaux  
16 Universitaires La Pitié Salpêtrière, Paris, France

17 <sup>8</sup>Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA

18 <sup>9</sup>Department of Pathology, Brigham and Women's Hospital, Boston, MA

19 <sup>10</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA

20  
21 **Running head:** TMZ vs PCV for WHO grade III Oligodendroglioma

22  
23 **Corresponding author:**

24 J. Bryan Iorgulescu, M.D.

25 Department of Pathology, Brigham and Women's Hospital

26 Department of Medical Oncology, Dana-Farber Cancer Institute

27 Harvard Medical School

28 75 Francis St., Boston, MA 02115

29 Phone: 617-732-7510, Fax: 617-277-9015

30 [jiorgulescu@bwh.harvard.edu](mailto:jiorgulescu@bwh.harvard.edu)

31  
32 This work was presented in part at the 2019 annual meeting of the Society for Neuro-Oncology.

36 **Abstract**

37 **PURPOSE:** The optimal chemotherapy regimen between temozolomide (TMZ) and procarbazine,  
38 lomustine, and vincristine (PCV) remains uncertain for newly-diagnosed anaplastic oligodendroglioma  
39 (AO). We therefore addressed this question using a national database.

40 **METHODS:** Patients newly-diagnosed with 1p/19q-codeleted W.H.O. grade III AO between 2010-  
41 2016 were identified from the National Cancer Database. Predictors of receiving first-line single-agent  
42 TMZ vs. multi-agent PCV were assessed by multivariable logistic regression. Overall survival (OS) was  
43 estimated by Kaplan-Meier techniques and evaluated by multivariable Cox regression.

44 **RESULTS:** 1,360 AO patients were identified: 74.5% (n=1,013) treated with TMZ, 9.6% (n=131) with  
45 PCV, and 15.9% (n=216) with no chemotherapy in the first-line setting. In multivariable logistic analysis,  
46 PCV utilization increased from 2010 to 2016 (OR=1.38/year, 95%CI: 1.22-1.56, p<0.001) and was less  
47 commonly utilized in privately insured patients (OR=0.38 vs. uninsured, 95%CI: 0.15-0.97, p=0.04). In  
48 survival analyses (33.1% reached endpoint), there was no difference in unadjusted OS between TMZ  
49 (5yr-OS 60.1%, 95%CI: 55.9-64.1) and PCV (5yr-OS 61.1%, 95%CI: 45.6-73.5; p=0.42). There  
50 remained no OS difference between TMZ and PCV in the 75.9% (n=1,032) of AO patients that also  
51 received radiotherapy (p=0.51), in the Cox regression analysis adjusted by age, extent of resection, and  
52 radiotherapy (TMZ vs. PCV HR=1.31, 95%CI: 0.83-2.08, p=0.24), and in subgroup analyses that  
53 incorporate KPS or *MGMT* status.

54 **CONCLUSIONS:** In a national database of AOs managed in the ‘real-world’ setting, there is no  
55 difference in the short-term mortality between first-line TMZ and PCV chemotherapy. These findings  
56 provide preliminary data while we await the long-term results from the CODEL trial.

57

58 **Key Words:** Anaplastic oligodendroglioma, Chemotherapy, Temozolomide, PCV

59 **Declarations:** The authors have no declarations.

60 **Funding:** JBI is supported by an NIH 5T32HL007627 award.

61 **Conflicts of interest:** The authors report no conflicts of interest.

62 **Availability of data and material:** Data are publicly available by application to the American College of  
63 Surgeons in accordance with the National Cancer Database's data use agreement.

64 **Code availability:** Available upon request.

65 **Authors' contributions:** Conception and study design: JBI. Data collection: NL, MM, VK. Data  
66 analysis: JBI. Data interpretation and Manuscript writing: All authors. Critical review and revisions: All  
67 authors.

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

## 85 Introduction

86 Diffuse gliomas are a common primary intracranial tumor associated with significant morbidity  
87 and mortality.<sup>1</sup> W.H.O. grade III anaplastic oligodendrogliomas (AOs) are a rare subset of diffuse  
88 gliomas, comprising about 6% of all gliomas, and, per the 2016 W.H.O. classification, are defined by the  
89 presence of both an *IDH* mutation and 1p/19q chromosomal codeletion.<sup>2</sup> The 1p/19q chromosomal  
90 codeletion is a strong prognostic marker associated with increased responsiveness to chemotherapy and  
91 superior outcomes in patients with diffuse gliomas.<sup>3,4</sup> However, despite recent advances in understanding  
92 its distinct molecular profile, the optimal therapeutic regimen for newly-diagnosed AOs remains unclear  
93 and controversial.<sup>5</sup>

94 The NCCN guidelines (version 3.2019) currently recommend maximal safe surgical resection  
95 followed by radiotherapy (RT) and chemotherapy for AOs.<sup>4,6</sup> The addition of chemotherapy to RT in  
96 patients with AO stems from two major randomized controlled trials that demonstrated improved survival  
97 among patients harboring a 1p/19q-codeletion who received procarbazine, lomustine, and  
98 vincristine (PCV) chemotherapy with RT, as compared to those who received RT alone.<sup>7,8</sup> More recently,  
99 in light of the results of the EORTC 26981–22981/NCIC CE3 trial, as well as evidence demonstrating  
100 that temozolomide (TMZ) may have a lower toxicity profile and more convenient administration than  
101 PCV, there has been interest in assessing whether TMZ might replace PCV in the treatment of AOs.<sup>4</sup> The  
102 CODEL trial (NCT00887146), which presently randomizes newly-diagnosed oligodendroglioma patients  
103 to RT with either adjuvant PCV or with concomitant TMZ (followed by adjuvant TMZ), is expected to  
104 answer this question in the future;<sup>9</sup> however, until its results become available, there is no clear consensus  
105 among the neuro-oncology community as to which regimen to use in the management of patients with  
106 AOs.<sup>5</sup>

107 Given the concerns surrounding PCV-related toxicity, we sought to compare outcomes for newly-  
108 diagnosed AO patients following TMZ or PCV in the first-line setting using a large national cancer  
109 database. As the results of the CODEL trial are years away, our study has the potential to offer clinical  
110 guidance about the efficacy of these regimens in the management of patients with newly-diagnosed AO.

111

## 112 **Materials and Methods**

### 113 *Data Source and Study Design*

114       The National Cancer Database (NCDB) is a nationwide database comprising more than 70% of  
115 newly diagnosed cancers in the United States.<sup>10</sup> Patients were identified with histologically-confirmed  
116 newly-diagnosed diffuse gliomas between 2010 (1p/19q codeletion data are only incorporated in the  
117 NCDB as of 2010) and 2016, as defined by the ICD-O-3 histological codes (*i.e.* 9380-9382, 9400-9401,  
118 9420, 9440-9442, 9450-9451, and 9460), a malignant behavior code (*i.e.* 3), and any brain site code (*i.e.*  
119 71.0-71.9).<sup>11</sup> Anaplastic oligodendrogliomas were defined herein using the primary brain-specific  
120 variables for W.H.O. grade III and for loss of heterozygosity/deletion of both chromosome arms 1p and  
121 19q.<sup>12</sup> A subset of cases with 1p/19q-codeletion were encoded in the NCDB as W.H.O. grade IV – likely  
122 reflecting the outmoded “glioblastoma with oligodendroglial features” – and herein were reclassified as  
123 W.H.O. grade III AOs in accordance with the revised 2016 W.H.O. classification. Patients were excluded  
124 if they had a prior diagnosis of cancer (thereby excluding W.H.O. grade II oligodendrogliomas that  
125 subsequently transformed into AO), were <20-years-old at diagnosis, were diagnosed at an index  
126 institution and treated entirely elsewhere, or if they were not 1p/19q-codeleted. Patients were also  
127 excluded if they lacked complete data regarding receipt of chemotherapy or RT.

128

### 129 *Variables and Statistical Analyses*

130       Chemotherapy is encoded in the NCDB as single-agent or multi-agent, without further details. In  
131 order to confirm that single-agent referred to temozolomide and multi-agent to PCV, we reviewed all  
132 encoded chemotherapy data for AOs from registry-submitted data from two cancer centers (Brigham and  
133 Women’s Hospital/Dana-Farber Cancer Center and Massachusetts General Hospital) and validated their  
134 encoding using the medical records. Associations between clinicopathologic factors, including age at  
135 diagnosis, sex, race/ethnicity, Charlson-Deyo comorbidity index, year of diagnosis, insurance status,  
136 hospital type and location, tumor size (greatest dimension), extent of resection (EOR), and receipt of

137 single-agent vs. multi-agent chemotherapy were assessed with multivariable logistic regression. Brain-  
138 specific EOR was stratified as biopsy-only, subtotal resection, or gross total resection. *IDH* mutation  
139 status is not encoded in the NCDB.

140 As previously described, overall survival (OS) was measured from the date of AO diagnosis to  
141 the date of death, with patients censored at the date of most recent follow-up.<sup>12,13</sup> OS was estimated by  
142 Kaplan-Meier methods and compared by log-rank tests and Cox regression analysis. Multivariable Cox  
143 proportional hazards regression was used to evaluate the association between chemotherapy regimen and  
144 OS. Due to limited follow-up, the NCDB excludes OS data for patients diagnosed in the final year of the  
145 dataset, which for this dataset was 2016 – therefore AO patients diagnosed in 2016 are excluded from  
146 survival analyses. Because Karnofsky performance status (KPS, stratified as  $\leq 60$  vs.  $>60$ ) and *MGMT*  
147 promoter methylation status were only encoded in a minority of patients (17.2% and 32.5% herein,  
148 respectively), these variables were separately added to the multivariable Cox regression analysis as  
149 subgroup analyses. STATA (v. 14.2, StataCorp) was used for statistical analyses, with 2-sided p-values  
150  $<0.05$  specified as significant. This study was approved by the Partners HealthCare institutional review  
151 board (#2015P002352).

152

## 153 **Results**

154 1,360 U.S. patients with newly-diagnosed 1p/19q-codeleted W.H.O. grade III AOs were  
155 identified; of whom 74.5% (n=1,013) received single-agent chemotherapy, 9.6% (n=131) received multi-  
156 agent chemotherapy, and 15.9% (n=216) had no chemotherapy in the first-line setting. From two of the  
157 NCDB's institutions, 73 1p/19q-codeleted AOs treated with chemotherapy between 2000-2017 were  
158 encoded and submitted to registries. Of these, 84.9% (n=62) and 15.1% (n=11) were encoded as first-line  
159 single-agent and multi-agent chemotherapy and were validated by medical chart review to represent TMZ  
160 and PCV, respectively, in all cases.

161 In multivariable logistic analysis of the national sample, privately insured patients were  
162 significantly less likely to receive multi-agent PCV (odds ratio [OR] 0.38, 95% confidence interval [CI]:

163 0.15-0.97,  $p=0.04$ ) than uninsured patients (Table 1). AOs that were more recently diagnosed, however,  
164 were significantly associated with increased utilization of PCV (OR 1.38/year, 95%CI: 1.22-1.56,  
165  $p<0.001$ ). Receipt of single-agent TMZ vs. multi-agent PCV chemotherapy was otherwise independent of  
166 AO patients' sex, age, race/ethnicity, comorbidity index, EOR, RT, tumor size (greatest dimension),  
167 hospital type, or hospital geographic location (all  $p>0.05$ , Table 1). 75.9% ( $n=1,032$ ) of AO patients also  
168 received RT (42.7% as 60 Gy and 33.2% as 59.4 Gy). RT began a median of 36 days (interquartile range  
169 [IQR] 28-47) after definitive resection; and single-agent TMZ chemotherapy often began on the same day  
170 as RT (median difference 0 days, IQR: 0-0), whereas multi-agent PCV chemotherapy often began  
171 following RT (median difference 64 days, IQR: 0-78.5; t-test  $p<0.001$ ).

172 In terms of OS, the median follow-up was 27.7 months (interquartile range [IQR] 12.4-49.9  
173 months) with 33.1% of patients reaching the endpoint of mortality in the national sample. Unadjusted OS  
174 estimates were not significantly different between single-agent TMZ (5yr-OS 60.1%, 95%CI: 55.9-64.1)  
175 and multi-agent PCV chemotherapy (5yr-OS 61.1%, 95%CI: 45.6-73.5; Cox regression  $p=0.42$ ), but both  
176 were significantly better than no chemotherapy (5yr-OS 46.5%, 95%CI: 36.8-55.7,  $p\leq 0.001$ ; Fig. 1). In  
177 the 1,032 patients who also had RT, there remained no significant OS difference between TMZ (5yr-OS  
178 56.1%, 95%CI: 51.4-60.6) and PCV (5yr-OS 54.0%, 95%CI: 36.0-68.9,  $p=0.51$ ). In the 15.9% of AO  
179 patients who did not receive chemotherapy, 53.5% had resection alone, 19.8% had resection with RT, and  
180 4.8% had biopsy with RT.

181 In multivariable Cox regression analysis adjusted for age, EOR, and RT – factors previously  
182 shown to have prognostic value in AOs – there was no difference in OS between first-line TMZ (HR 1.31,  
183 95%CI: 0.83-2.08,  $p=0.24$ ) and PCV chemotherapy, and either regimen significantly improved OS  
184 compared to no chemotherapy (Table 2). The lack of an OS difference persisted in subgroup analyses that  
185 incorporated KPS ( $n=188$ , TMZ HR 0.92 vs. PCV, 95%CI: 0.12-6.94,  $p=0.94$ ) and *MGMT* promoter  
186 methylation status ( $n=265$ , TMZ HR 1.04 vs. PCV, 95%CI: 0.50-2.16,  $p=0.91$ ).

187

188 **Discussion**

189 In this national analysis of 1,360 patients with newly-diagnosed 1p/19q-codeleted W.H.O. grade  
190 III anaplastic oligodendroglioma, we found no significant difference in short-term OS between patients  
191 treated with first-line single-agent (TMZ-based) vs. multi-agent (PCV-based) chemotherapy regimens.  
192 These findings persisted after adjusting for key prognostic variables of age at diagnosis, EOR, and RT,  
193 together providing support for the similarity of short-term OS outcomes for first-line TMZ vs. PCV in this  
194 patient population.

195 Two landmark trials established the chemosensitivity of 1p/19q-codeleted oligodendrogliomas  
196 and defined a role for PCV in the treatment of AOs: Radiation Therapy Oncology Group (RTOG) 9402  
197 and the European Organization for Research and Treatment of Cancer (EORTC) 26951 both showed that  
198 among patients with 1p/19q-codeleted tumors, treatment with RT and PCV resulted in significant  
199 improvements in OS as compared to treatment with adjuvant RT alone.<sup>7,8</sup> However, despite the  
200 compelling evidence in favor of adjuvant PCV, its use in clinical practice has been limited by its  
201 significant toxicity.<sup>14</sup> Specifically, lomustine can cause bone marrow suppression and procarbazine can  
202 result in intractable nausea and skin reactions that require its discontinuation. In addition, vincristine is  
203 not thought to achieve appreciable penetration of the blood-brain-barrier, potentially limiting the overall  
204 efficacy of PCV in the treatment of an intracranial tumor.<sup>15</sup> In light of patients' poor tolerance of and  
205 ability to complete treatment with PCV, TMZ has also been explored as a potential alternative in the  
206 treatment of AOs.

207 Numerous retrospective studies have demonstrated that TMZ may be a safe and efficacious  
208 alternative for AO treatment, achieving similar response rates as chemotherapy with PCV. In a clinical  
209 efficacy trial of 20 patients with AO, TMZ was given for up to 24 weeks following surgical resection:  
210 results demonstrated a high response to TMZ, with clinical improvement reported in 60% of patients and  
211 only two reports of grade 3/4 toxicity.<sup>16</sup> Similarly, another phase II study assessed the use of upfront TMZ  
212 in the treatment of newly-diagnosed AO and found a median progression-free survival (PFS) of 62  
213 months, with limited high-grade toxicities despite a dose-intense schedule.<sup>17</sup> Robust tumor responsiveness  
214 and well-managed toxicity following TMZ for AO have been consistently observed in retrospective



215 studies.<sup>18,19</sup> It should be noted, however, that none of the above studies included RT, so it is possible that  
216 response rates might have been even higher had RT been added to TMZ therapy, although toxicity  
217 profiles may also have been more severe.

218         Despite these reports suggesting an opportunity for TMZ in first-line treatment of AO, whether  
219 TMZ can outperform PCV remains uncertain. There have been a limited number of retrospective studies  
220 that have attempted to compare these two chemotherapy regimens head-to-head; ever fewer of which  
221 have incorporated the 2016 revised W.H.O. histomolecular definitions of AOs. In a large multi-  
222 institutional retrospective study by Lassman *et al.*, in which only 89 1p/19q-codeleted AOs were  
223 compared by chemotherapy agent, PCV-alone demonstrated improved time-to-progression (median 7.6  
224 months compared to 3.3 months in TMZ-alone,  $p=0.02$ ), but no difference in OS ( $p=0.16$ ).<sup>20</sup> In the AOs  
225 that also received RT, there was no difference in either time-to-progression or OS for PCV vs. TMZ.<sup>20</sup> In  
226 the Neuro-Oncology Working Group (NOA) phase III trial NOA-04, in which patients with anaplastic  
227 gliomas (only 69 with 1p/19q-codeletion) were randomized to upfront RT or upfront chemotherapy  
228 (either PCV or TMZ), researchers ultimately found that chemotherapy alone was not superior to RT.<sup>21</sup> In  
229 the subset ( $n=33$ ) of CpG island hypermethylated (CIMP) 1p/19q-codeleted cases, PCV-alone  
230 demonstrated improved PFS, but not OS, compared to TMZ-alone. Notably, although NOA-04  
231 demonstrated better tumor control with PCV, it also demonstrated worse toxicity with PCV. Among the  
232 anaplastic glioma patients treated with upfront chemotherapy, treatment was discontinued in 33% of  
233 patients treated with PCV ( $n=54$ ), all due to toxicity, while none of the TMZ-treated patients ( $n=53$ )  
234 required TMZ discontinuation due to toxicity.<sup>22</sup> Although the Lassman *et al.* study and NOA-04 had  
235 moderate follow-up durations of approximately 10 years, it is highly likely that their data had not yet  
236 reached maturity and were underpowered with respect to the question of PCV vs. TMZ for AOs. Similar  
237 to these studies, our data only capture the short-term outcomes of PCV vs. TMZ for AOs, and it is  
238 possible that with much longer follow-up one regimen may prove superior at later landmarks. To  
239 rigorously answer this question the phase III CODEL trial (NCT00887146) has been redesigned as a  
240 randomized noninferiority comparison of RT either followed by adjuvant PCV or with concomitant TMZ

241 followed by adjuvant TMZ for grade II and III newly-diagnosed 1p/19q-codeleted oligodendrogliomas,  
242 powered for PFS, and secondarily assessing OS, toxicity, and quality of life outcomes.

243 Because the final results of CODEL are likely years away, we evaluated the short-term OS  
244 outcomes associated with PCV or TMZ as first-line treatment in a contemporary national cohort of 1,360  
245 patients with newly-diagnosed 1p/19q-codeleted AOs. Nationally, utilization of TMZ vs. PCV was  
246 significantly affected by insurance status: nearly twice as many uninsured AO patients received PCV as  
247 privately insured patients – suggesting that insurance-related financial barriers may pose challenges to  
248 TMZ access. Although prior work has suggested that TMZ may be surpassing PCV as the regimen-of-  
249 choice for gliomas given the favorable toxicity profiles of TMZ,<sup>23</sup> in our analysis utilization of PCV  
250 actually increased for AOs from 2010 to 2016. This increase may reflect the timely publication of results  
251 from the RTOG 9402 and EORTC 26951 randomized controlled trials, which firmly established the  
252 survival benefit of adding PCV to RT for 1p/19q-codeleted gliomas. TMZ vs. PCV rates were otherwise  
253 independent of patient age, sex, comorbidity status, tumor size, hospital type and location, RT, and EOR.  
254 In line with the studies' survival findings above, we found no difference in short-term OS between AOs  
255 treated with first-line PCV versus TMZ. This included in the setting of RT, as well as after multivariable  
256 adjustment for age, EOR, RT, *MGMT* promoter methylation status, and/or KPS.

257

### 258 *Limitations*

259 Although our analysis encompasses a national dataset, the NCDB's limited encoding of 1p/19q-  
260 codeletion status only as of 2010 constrained our follow-up to a median of 28 months. As a result, our  
261 findings only apply to the short-term outcomes of 1p/19q-codeleted AO patients and do not capture any  
262 delayed differences between PCV and TMZ. Based on a two-tailed log-rank power analysis using the  
263 Schoenfeld method, this sample set has 90% power to detect a 0.56 HR between the OS of TMZ and  
264 PCV. Although only results from a randomized trial comparing PCV and TMZ will be able to ultimately  
265 answer this question, our findings suggest that either PCV or TMZ may offer comparable early OS

266 outcomes in the first-line management of newly-diagnosed AOs and support the tailoring of the TMZ vs.  
267 PCV selection to each patient's unique circumstances.

268 Even though national registry-based databases like the NCDB provide an unparalleled look at  
269 outcomes in a real-life treatment population, they are constricted by several key limitations. First-line  
270 chemotherapy is encoded as single-agent and multi-agent, without details about agents, doses, early and  
271 late toxicities, or duration of treatment. To help address this limitation, registry-submitted data for AOs  
272 from two institutions were evaluated, in which all single-agent cases were TMZ and all multi-agent cases  
273 were PCV. Furthermore, only the initial courses of therapy are encoded in the NCDB, so it is possible that  
274 some cases received additional single-agent or multi-agent chemotherapy as second-line therapy.  
275 Molecular data are also very limited in registry data: 1p/19q-codeletion status was only incorporated as of  
276 2010, resulting in a median follow-up for this analysis of 28 months, without details about the diagnostic  
277 methodology. *IDH* mutational status is presently lacking in registry data, so all oligodendrogliomas herein  
278 were defined by their 1p/19q-codeletion and thus were also likely *IDH* mutant.<sup>11</sup> *MGMT* promoter  
279 methylation was encoded in a minority of cases, but CpG island hypermethylation data are not included.  
280 Additionally, only OS is encoded for outcomes, precluding the evaluation of PFS for PCV vs. TMZ in  
281 AOs.

282

### 283 *Conclusions*

284 In this study of 1,360 patients with newly-diagnosed 1p/19q-codeleted AO, we found no  
285 difference in the short-term OS between first-line multi-agent PCV and single-agent TMZ chemotherapy,  
286 including in the setting of RT. In addition, we found overall utilization of PCV to be on the rise between  
287 2010 and 2016, and that uninsured patients were significantly more likely to receive PCV than privately  
288 insured patients – suggesting that there may exist insurance-related financial barriers to the access of  
289 TMZ. While results from the CODEL trial will ultimately offer guidance with respect to optimal  
290 management for patients with newly-diagnosed AO, our results offer preliminary evidence that both TMZ  
291 and PCV chemotherapy regimens may be viable options in the first-line setting.

292

293 **Acknowledgements:** The authors are grateful to the cancer registrars at BWH/DFCI and MGH for their

294 invaluable assistance in data acquisition. JBI acknowledges support by the NIH (T32HL007627).

295

296 **References**

- 297 1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central  
298 nervous system tumors diagnosed in the United States in 2010-2014. *Neuro-Oncol.* 2017.  
299 doi:10.1093/neuonc/nox158
- 300 2. Louis DN, Ohgaki H, Cavenee WK. *World Health Organization Histological Classification of*  
301 *Tumours of the Central Nervous System.* Vol 1. revised 4th. France: International Agency for  
302 Research on Cancer; 2016.
- 303 3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic  
304 response and survival in patients with anaplastic oligodendrogliomas. *J Natl Cancer Inst.* 1998.  
305 doi:10.1093/jnci/90.19.1473
- 306 4. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. *JAMA.*  
307 2013. doi:10.1001/jama.2013.280319
- 308 5. Ruff MW, Buckner JC, Johnson DR, van den Bent MJ, Geurts M. Neuro-Oncology Clinical Debate:  
309 PCV or temozolomide in combination with radiation for newly diagnosed high-grade  
310 oligodendroglioma. *Neuro-Oncol Pract.* 2019;6(1):17-21. doi:10.1093/nop/npy044
- 311 6. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. version 3.2019  
312 (November 11,2019) [https://www.nccn.org/professionals/physician\\_gls/pdf/cns\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf).
- 313 7. Van Den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and  
314 vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up  
315 of EORTC brain tumor group study 26951. *J Clin Oncol.* 2013. doi:10.1200/JCO.2012.43.2229
- 316 8. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic  
317 oligodendroglioma: Long-term results of RTOG 9402. *J Clin Oncol.* 2013.  
318 doi:10.1200/JCO.2012.43.2674
- 319 9. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO)  
320 guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet*  
321 *Oncol.* 2017. doi:10.1016/S1470-2045(17)30194-8

- 322 10. Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for Outcomes Research: A  
323 Review. *JAMA Oncol.* 2017;3(12):1722-1728. doi:10.1001/jamaoncol.2016.6905
- 324 11. Iorgulescu JB, Torre M, Harary M, et al. The Misclassification of Diffuse Gliomas: Rates and  
325 Outcomes. *Clin Cancer Res.* 2019;25(8):2656-2663. doi:10.1158/1078-0432.CCR-18-3101
- 326 12. Harary M, Kavouridis VK, Torre M, et al. Predictors and early survival outcomes of maximal  
327 resection in WHO grade II 1p/19q-codeleted oligodendrogliomas. *Neuro-Oncol.* September 2019.  
328 doi:10.1093/neuonc/noz168
- 329 13. Iorgulescu JB, Harary M, Zogg CK, et al. Improved Risk-Adjusted Survival for Melanoma Brain  
330 Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort.  
331 *Cancer Immunol Res.* July 2018. doi:10.1158/2326-6066.CIR-18-0067
- 332 14. Ruff MW, Buckner JC, Johnson DR, Van Den Bent MJ, Geurts M. Neuro-oncology clinical debate:  
333 Pcv or temozolomide in combination with radiation for newly diagnosed high-grade  
334 oligodendroglioma. *Neuro-Oncol Pract.* 2019. doi:10.1093/nop/npy044
- 335 15. Boyle FM, Eller SL, Grossman SA. Penetration of intra-arterially administered vincristine in  
336 experimental brain tumor. *Neuro-Oncol.* 2004. doi:10.1215/s1152851703000516
- 337 16. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T. Temozolomide treatment for newly diagnosed  
338 anaplastic oligodendrogliomas: A clinical efficacy trial. *J Neurooncol.* 2006. doi:10.1007/s11060-  
339 005-9020-1
- 340 17. Ahluwalia MS, Xie H, Dahiya S, et al. Efficacy and patient-reported outcomes with dose-intense  
341 temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a  
342 phase II multicenter study. *J Neurooncol.* 2015. doi:10.1007/s11060-014-1684-y
- 343 18. Mikkelsen T, Doyle T, Anderson J, et al. Temozolomide single-agent chemotherapy for newly  
344 diagnosed anaplastic oligodendroglioma. *J Neurooncol.* 2009. doi:10.1007/s11060-008-9735-x
- 345 19. Ducray F, Sierra Del Rio M, Carpentier C, et al. Up-front temozolomide in elderly patients with  
346 anaplastic oligodendroglioma and oligoastrocytoma. *J Neurooncol.* 2011. doi:10.1007/s11060-010-  
347 0264-z

- 348 20. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000  
349 adults with anaplastic oligodendroglial tumors. *Neuro-Oncol.* 2011. doi:10.1093/neuonc/nor040
- 350 21. Wick W, Society for the NWG (NOA) of the GC, Roth P, et al. Long-term analysis of the NOA-04  
351 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or  
352 temozolomide. *Neuro-Oncol.* 2016.
- 353 22. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential  
354 radiochemotherapy of anaplastic glioma with Procarbazine, Lomustine, and Vincristine or  
355 Temozolomide. *J Clin Oncol.* 2009. doi:10.1200/JCO.2009.23.6497
- 356 23. Yu T, Kang HC, Lim DH, et al. Pattern of care of anaplastic oligodendroglioma and  
357 oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. *J*  
358 *Neurooncol.* 2015. doi:10.1007/s11060-014-1660-6

359

360

361 **Fig 1** There is no difference in the unadjusted OS curves between single-agent TMZ (solid line) and  
362 multi-agent PCV (dashed line) treatment for AOs (Cox regression p=0.42)

363

364

365

366

367 **Table 1.** Multivariable logistic regression analysis of factors associated with utilization of PCV, as  
 368 compared to TMZ.

	<b>total n had chemo</b>	<b>% had PCV</b>	<b>OR of PCV</b>	<b>95%CI</b>	<b>p- value</b>
<b>Age (yr)</b>					
<40	295	13.2 %	2.01	(0.24-16.89)	0.52
40-49	281	10.7 %	0.96	(0.53-1.76)	0.90
50-59	281	10.7 %	Reference		
≥60	287	11.2 %	0.83	(0.44-1.57)	0.57
<b>Sex</b>					
Male	663	12.4 %	Reference		
Female	481	10.2 %	0.75	(0.49-1.17)	0.21
<b>Charlson-Deyo comorbidity index</b>					
0	937	11.7 %	Reference		
1	138	13.0 %	1.22	(0.65-2.28)	0.54
2+	69	4.4 %	0.26	(0.06-1.11)	0.07
<b>Race/Ethnicity</b>					
White, non-Hispanic	954	10.7 %	Reference		
Black, non-Hispanic	43	9.3 %	0.83	(0.27-2.49)	0.74
Asian/Pacific islander	40	12.5 %	0.97	(0.32-2.96)	0.95
Hispanic	83	22.9 %	1.56	(0.79-3.06)	0.20
<b>Year of diagnosis</b>			1.38	(1.22-1.56)	<b>&lt;0.001</b>
<b>Primary payor status</b>					
Uninsured	43	18.6 %	Reference		
Private insurance	777	10.8 %	0.38	(0.15-0.97)	<b>0.04</b>
Medicare/Medicaid/Other governmental	309	12.0 %	0.46	(0.17-1.26)	0.13
<b>Cancer hospital type</b>					
Academic/NCI-designated program	525	11.4 %	Reference		
Community program	216	9.7 %	0.58	(0.30-1.12)	0.11
Integrated network program	108	10.2 %	0.77	(0.35-1.69)	0.52
Suppressed due to age<40*	295	13.2 %	collinear with age<40		
<b>Hospital location (US Census Division)</b>					
New England (CT, MA, ME, NH, RI, VT)	50	4.0 %	0.91	(0.07-11.19)	0.94
Middle Atlantic (NJ, NY, PA)	161	13.7 %	3.91	(0.47-32.55)	0.21
S. Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, WV)	133	11.3 %	3.06	(0.36-26.11)	0.31
E. N. Central (IL, IN, MI, OH, WI)	146	6.9 %	1.40	(0.16-12.47)	0.77
E. S. Central (AL, KY, MS, TN)	36	11.1 %	Reference		
W. N. Central (IA, KS, MN, MO, ND, NE, SD)	97	11.3 %	4.09	(0.47-35.28)	0.20
W. S. Central (AR, LA, OK, TX)	47	8.5 %	1.73	(0.17-17.98)	0.65
Mountain (AZ, CO, ID, MT, NM, NV, UT, WY)	61	13.1 %	5.29	(0.57-49.32)	0.14
Pacific (AK, CA, HI, OR, WA)	118	13.6 %	2.94	(0.35-24.90)	0.32



Suppressed due to age<40*	295	13.2 %	collinear with age<40		
<b>Extent of resection</b>					
Biopsy-only	203	8.9 %	Reference		
Subtotal resection	335	11.9 %	1.20	(0.64-2.26)	0.57
Gross total resection	438	11.9 %	1.24	(0.67-2.26)	0.50
<b>Radiotherapy</b>					
No	167	12.0 %	Reference		
Yes	977	11.4 %	0.64	(0.36-1.16)	0.14
<b>Tumor size, greatest dimension (cm)</b>					
≤2.0	46	15.2 %	2.10	(0.76-5.82)	0.15
2.1-4.0	203	11.8 %	Reference		
4.1-6.0	343	11.1 %	0.86	(0.45-1.64)	0.65
>6.0	301	11.3 %	1.02	(0.53-1.95)	0.96
n/a	251	11.2 %	0.97	(0.49-1.91)	0.93

369 Abbreviations: Odds ratio (OR); confidence interval (CI); temozolomide (TMZ); procarbazine, lomustine,  
 370 and vincristine (PCV). \*To ensure de-identification, the NCDB excludes cancer hospital type and location  
 371 data for patients <40-years-old, thus these groups are collinear with the <40-year-old age group in  
 372 multivariable regression.

373

374

375

376

377

378

379

380

381

382

383

384

385


386

387 **Table 2.** Multivariable Cox regression analysis of OS in AOs.

	<b>HR</b>	<b>95%CI</b>	<b>p-value</b>
<b>Chemotherapy</b>			
None	Reference		
TMZ	0.51	(0.38-0.68)	<b>&lt;0.001</b>
PCV	0.39	(0.23-0.65)	<b>&lt;0.001</b>
<b>Age (yr)</b>			
<40	0.84	(0.54-1.29)	0.42
40-49	Reference		
50-59	2.52	(1.76-3.62)	<b>&lt;0.001</b>
60+	4.19	(2.96-5.93)	<b>&lt;0.001</b>
<b>Extent of resection</b>			
Biopsy-only	Reference		
Subtotal resection	0.58	(0.44-0.77)	<b>&lt;0.001</b>
Gross total resection	0.60	(0.46-0.78)	<b>&lt;0.001</b>
<b>Radiotherapy</b>			
Yes (ref no)	1.27	(0.95-1.69)	0.11

388 Abbreviations: Hazard ratio (HR); confidence interval (CI); temozolomide (TMZ); procarbazine,

389 lomustine, and vincristine (PCV).



Number at risk		Overall survival (mos)						
		0	12	24	36	48	60	72
No chemo	176	176	98	73	53	35	22	14
TMZ	853	853	674	511	375	250	145	73
PCV	92	92	83	56	33	17	7	5